|
|
|
|
|
|
Sponsors and Collaborators: |
University of California, Davis University of California, San Francisco Genentech |
Information provided by: | University of California, Davis |
ClinicalTrials.gov Identifier: | NCT00517010 |
Because a possible synergism of radiation and inhibitors of vascular endothelial growth factor has been shown in cancer patients and patients with wet macular degeneration, this pilot study is being conducted to determine whether treating wet macular degeneration with a combination of Lucentis and proton beam irradiation is safe. Lucentis is an inhibitor of vascular endothelial growth factor which was recently FDA approved for treatment of wet macular degeneration. It appears to be the most effective therapy thus far for wet macular degeneration among all drugs FDA approved for this condition. If no major safety issues are associated with this combination therapy, a larger study will be conducted to determine whether this combination therapy is more effective than Lucentis monotherapy. l
Condition |
Age-Related Macular Degeneration |
Genetics Home Reference related topics: | X-linked juvenile retinoschisis |
MedlinePlus related topics: | Macular Degeneration |
ChemIDplus related topics: | Ranibizumab |
Study Type: | Observational |
Study Design: | Cohort, Prospective |
Official Title: | Phase 1 Pilot Open Label Prospective Observational Study of Safety and Tolerability of Lucentis Combined With Proton Beam Irradiation in Treating Exudative Age-Related Macular Degeneration |
Estimated Enrollment: | 10 |
Study Start Date: | May 2007 |
Estimated Study Completion Date: | May 2009 |
Ten subjects diagnosed with wet macular degeneration will be treated with standard of care, i.e. intravitreal Lucentis injection monthly for the first four months and as needed thereafter. Within six weeks of the first Lucentis injection, the eye will also be treated with 24 Gy of proton beam divided into two fractions. Each subject will be followed for 2 yrs with monthly examination.
Ages Eligible for Study: | 50 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Sampling Method: | Probability Sample |
Patients seen or referred to the Retina Service for newly diagnosed exudative age-related macular degeneration
Inclusion Criteria:
Exclusion Criteria:
Contact: Barbara Holderreed | (916) 734-6303 | baholderreed@ucdavis.edu |
United States, California | |||||
Department of Ophthalmology & Vision Science, University of California Davis | Recruiting | ||||
Sacramento, California, United States, 95817 | |||||
Contact: Barbara Holderreed 916-734-6303 baholderreed@ucdavis.edu |
University of California, Davis |
University of California, San Francisco |
Genentech |
Principal Investigator: | Susanna S Park, MD PhD | University of California, Davis |
Responsible Party: | University of California Davis ( Susanna S. Park, MD PhD/Associate Professor ) |
Study ID Numbers: | 200715285, FVF4150s |
First Received: | August 15, 2007 |
Last Updated: | June 23, 2008 |
ClinicalTrials.gov Identifier: | NCT00517010 |
Health Authority: | United States: Food and Drug Administration; United States: Institutional Review Board |
|
|
|